5-05-2025, 18:49

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)

Notified -
Globe Newswire5-05-2025, 18:49
24-02-2025, 13:00

Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]

Notified -
Globe Newswire24-02-2025, 13:00
21-02-2025, 18:00

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

Notified -
Globe Newswire21-02-2025, 18:00
22-10-2024, 18:00

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
Globe Newswire22-10-2024, 18:00
25-07-2024, 12:00

Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases
Globe Newswire25-07-2024, 12:00
1-07-2024, 12:00

FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
Globe Newswire1-07-2024, 12:00
22-04-2024, 12:00

Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
Globe Newswire22-04-2024, 12:00